To explore further, we used whole exome sequencing to explore the genetic changes in the granulocytes of 26 paired MPN patients with or without SC. Epidemiological studies have confirmed the excessive risk of SCs in MPNs, but little is known about their molecular basis. With the indolent nature of the diseases, second cancers (SCs) have emerged as a challenging issue in afflicted patients. Patients with myeloproliferative neoplasms (MPNs) are characterized by systemic inflammation. Using RNA sequencing on pre- and post-treatment samples from one patient, we demonstrated altered expression of genes participating in IFN response, inflammation, apoptosis, and cellular differentiation.Ĭonclusively, observed signs of efficacy and safety in our real-world experience prove Ropeg as a promising option for the treatment of MPN. Furthermore, plasma hepcidin levels increased in two-thirds of PV patients, illustrating the potential of Ropeg to restore normal regulation of erythropoiesis. Although no specific patterns of cytokine level alteration could be identified, significantly attenuated plasma levels of inflammation markers were observed in one particular patient who happened to have normalized spleen size and most remarkable reduction in JAK2 mutant allele burden, indicating all-around improvement in every aspect of this case. The agent also showed efficacy in symptom amelioration and spleen size reduction. Most therapy-related side effects were mild, and there was no treatment discontinuation attributable to intolerable adverse events. Herein, we collected clinical data and assessed the safety as well as efficacy of Ropeg in nine patients treated in this program.Ĭollectively, among evaluable patients, both the molecular response and complete blood count remission rates were 62.5%. However, other than data from clinical trials, little is known about this agent in real world practice.Ī compassionate use program employing Ropeg for treating patients with unmet medical need was initiated in Taiwan in 2017.
It does not store any personal data.Ropeginterferon alpha-2b (Ropeg) is a novel pegylated interferon-alpha recently approved for the treatment of polycythemia vera (PV) in Europe. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". These cookies ensure basic functionalities and security features of the website, anonymously. Necessary cookies are absolutely essential for the website to function properly.
0 kommentar(er)
